What the FDA feedback means for Antisense Therapeutics

preview_player
Показать описание
Antisense Therapeutics has received formal written feedback from the US Food and Drug Administration (FDA) on its development plans for ATL1102 for non-ambulant patients with Duchenne muscular dystrophy (DMD).
Non- Executive Director Charmaine Gittleson discusses the implications.
Рекомендации по теме